Eye drops with a caspase-9 inhibitor prevent retinal injury from retinal vein occlusion. In the left image, RVO causes swelling in the retina and the retinal layers are less distinct. In the right image, the eye drops have restored the distinct layers of the retina. (Troy lab)
Researchers at Columbia University Irving Medical Center have developed eye drops that could prevent vision loss after retinal vein occlusion, a major cause of blindness for millions of adults worldwide.
A study, in mice, suggests that the experimental therapy—which targets a common cause of neurodegeneration and vascular leakage in the eye—could have broader therapeutic effects than existing drugs.
The study was published in Nature Communications.
What is Retinal Vein Occlusion?
Retinal vein occlusion occurs when a major vein that drains blood from the retina is blocked, usually due to a blood clot. As a result, blood and other fluids leak into the retina, damaging specialized light-sensing neurons called photoreceptors.
Standard treatment for the condition currently relies on drugs that reduce fluid leakage from blood vessels and abnormal blood vessel growth. But there are significant drawbacks. These therapies require repeated injections directly into the eye, and for the patients who brave this daunting prospect, the treatment ultimately fails to prevent vision loss in the majority of cases.
The new treatment targets an enzyme called caspase-9, says Carol M. Troy, MD, PhD, professor of pathology & cell biology and of neurology in the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain at Columbia University Vagelos College of Physicians and Surgeons, who led the studies. Under normal conditions, caspase-9 is believed to be primarily involved in programmed cell death, a tightly regulated mechanism for naturally eliminating damaged or excess cells.
In studies of mice, the Troy lab discovered that when blood vessels are injured by retinal vein occlusion, caspase-9 becomes uncontrollably activated, triggering processes that can damage the retina.
Eye Drops Prevent Retinal Injury
The Troy lab found that a highly selective caspase-9 inhibitor, delivered in the form of eye drops, improved a variety of clinical measures of retinal function in a mouse model of the condition. Most importantly, the treatment reduced swelling, improved blood flow, and decreased neuronal damage in the retina.
“We believe these eye drops may offer several advantages over existing therapies,” says Troy. “Patients could administer the drug themselves and wouldn’t have to get a series of injections. Also, our eye drops target a different pathway of retinal injury and thus may help patients who do not respond to the current therapy.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Retinal vein occlusion
- Intravitreal dexamethasone for macular edema may increase Intraocular Pressure: Study
A comprehensive retrospective study published in the Graefe's Archive for Clinical and Experimental Ophthalmology investigated the impact of steroidal medications on intraocular pressure (IOP) ...
- People over State Pension age with eyesight issues could be due up to £434 each month
Attendance Allowance could help people who are severely short-sighted or have eye conditions including cataract, glaucoma or macular degeneration.
- DWP could pay people with sight loss conditions up to £434 a month
The Department for Work and Pensions (DWP) could pay people of State Pension age up to £434 a month for certain sight loss conditions. This can be done through Attendance Allowance, reports the Daily ...
- Roche's Vabysmo shows no sign of slowdown after Regeneron and Bayer's launch of Eylea HD
It’s been eight months since Regeneron secured approval for a high-dose version of its powerhouse macular degeneration treatment Eylea in the U.S. | How much impact has the approval of high-dose Eylea ...
- EyePoint Pharmaceuticals gets grant for treatment of ocular conditions using multi-specific compounds
Discover the groundbreaking patent by EyePoint Pharmaceuticals for treating ocular conditions with multi-specific compounds targeting phosphatase and receptor tyrosine kinase agonists. Treat diabetic ...
Go deeper with Google Headlines on:
Retinal vein occlusion
[google_news title=”” keyword=”retinal vein occlusion” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Vascular dysfunction
- Buy Rating Affirmed: LeMaitre Vascular’s Growth and Profitability Outlook
Stifel Nicolaus analyst Rick Wise upgraded the rating on Lemaitre Vascular (LMAT – Research Report) to a Buy today, setting a price ...
- Stress and alcohol consumption increase risk of Alzheimer’s disease
Both alcohol consumption and stress exposure throughout life significantly heighten the risk of developing Alzheimer's disease and other dementias, through mechanisms that likely involve ...
- New surgeon joins Northern Light Vascular Care
Northern Light Vascular Care in Bangor is pleased to welcome Samuel Hui, MD, FACS to the team. Dr. Hui earned his medical education from Saba University ...
- Vascular Institute of New York receives coveted recognition for excellence
The Vascular Institute of New York located in Borough Park since 1990 has recently been recognized as a Verified Outpatient Vascular-VP Center by the American ...
- The VIVA Foundation Convenes Vascular Leaders Forum on CLTI
Aiming to explore the state of care for patients with chronic limb-threatening ischemia (CLTI), current clinical trial methodologies, and nuances of r ...
Go deeper with Google Headlines on:
Vascular dysfunction
[google_news title=”” keyword=”vascular dysfunction” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]